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Abstract
Background: The previously validated NK1-receptor ligand [O-methyl-11C]GR205171 binds with
a high affinity to the NK1-receptor and displays a slow dissociation from the receptor. Hence, it
cannot be used in vivo for detecting concentration changes in substance P, the endogenous ligand
for the NK1-receptor. A radioligand used for monitoring these changes has to enable displacement
by the endogenous ligand and thus bind reversibly to the receptor. Small changes in the structure
of a receptor ligand can lead to changes in binding characteristics and also in the ability to penetrate
the blood-brain barrier. The aim of this study was to use carbon-11 labelled ethyl and propyl iodide
with high specific radioactivity in the synthesis of two new and potentially reversible NK1-receptor
ligands with chemical structures based on [O-methyl-11C]GR205171.
Methods: [1-11C]Ethyl and [1-11C]propyl iodide with specific radioactivities of 90 GBq/μmol and
270 GBq/μmol, respectively, were used in the synthesis of [O-methyl-11C]GR205171 analogues by
alkylation of O-desmethyl GR205171. The brain uptake of the obtained (2S,3S)-N-(1-(2- [1-
11C]ethoxy-5-(3-(trifluoromethyl)-4H-1,2,4-triazol-4-yl)phenyl)ethyl)-2-phenylpiperidin-3-amine
(I)  and (2S,3S)-2-phenyl-N-(1-(2- [1-11C]propoxy-5-(3-(trifluoromethyl)-4H-1,2,4-triazol-4-
yl)phenyl)ethyl)piperidin-3-amine (II) was studied with PET in guinea pigs and rhesus monkeys and
compared to the uptake of [O-methyl-11C]GR205171.
Results: All ligands had similar uptake distribution in the guinea pig brain. The PET-studies in
rhesus monkeys showed that (II) had no specific binding in striatum. Ligand (I) had moderate
specific binding compared to the [O-methyl-11C]GR205171. The ethyl analogue (I)  displayed
reversible binding characteristics contrary to the slow dissociation rate shown by [O-methyl-
11C]GR205171.
Conclusion: The propyl-analogue (II) cannot be used for detecting changes in NK1-ligand levels,
while further studies should be performed with the ethyl-analogue (I).
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Background
Positron emission tomography (PET) has been used for
visualisation of cerebral energy consumption and receptor
distribution in the living brain using β+-emitting radiolig-
ands, i.e. tracers. A radioligand employed in brain recep-
tor mapping is generally desired to display a rapid
transport over the blood-brain barrier, a high affinity and
a selective binding to the receptor. As apposed to the high
affinity criteria in receptor mapping, a radioligand used in
concentration measurements of endogenous transmitters
in the vicinity of neuroreceptors should have an affinity
which enables displacement by an endogenous ligand [1-
4]. It is assumed that a radioligand with a very high affin-
ity to a receptor will not enable such detection.
There is a large interest in the development of antagonists
for the Neurokinin-1 (NK1) receptor system [5-10].
Recently Emend® (MK-869) was approved as a drug for
treatment of chemotherapy-induced nausea. Other possi-
ble therapeutic areas of NK1-receptor antagonists are not
fully defined yet, but their potential as drugs has been
explored in a range of disorders, including pain, inflam-
mation, depression and other psychiatric diseases [11-
14]. The endogenous NK1-receptor ligand, substance P, is
distributed in neurons within the central nervous system
[15]. The NK1-receptor system has showed a spatial over-
lap with neurotransmitters such as serotonin and
noradrenaline [16,17]. Substance P interacts with the ser-
otonergic neuronal systems via interneurons which lead
to an increase in synaptic availability of serotonin [18,19].
Previous studies has shown that NK1-receptors can be vis-
ualised  in vivo with the carbon-11 and fluorine-18
labelled NK1-receptor antagonists [O-methyl-
11C]GR205171 and [18F]SPA-RQ [20-22]. These two com-
pounds are based on the same pharmacophore and dis-
play a very high affinity for the NK1-receptor, hence they
can be used for visualisation of the receptor system. How-
ever, the compounds cannot be used for detecting changes
in substance P levels due to slow dissociation from the
receptor. Most attempts to develop in vivo NK1-receptor
radioligands have been unsuccessful or indifferent, except
for the two ligands mention above [23-26].
Recent developments in 11C-chemistry have opened for
new labelling methods beyond the use of methylation
and cyanation reactions. Carbonylation using [11C]car-
bon monoxide has shown to yield 11C-labelled carbonyl
compounds with high specific radioactivity and to enable
the synthesis of small libraries of labelled compounds
[27-31]. This may be useful in the development of PET-
tracers since it has been demonstrated that small changes
in the structure of a receptor ligand can lead to changes in
affinity and also in the ability to penetrate the blood-brain
barrier [32-34].
The aim of this study was to use labelled ethyl and propyl
iodide with high specific radioactivity in the synthesis of
[O-methyl-11C]GR205171-analogues with different alkyl
chain lengths and to compare the binding characteristics
in guinea pig and rhesus monkey. We hypothesised that
the increased alkyl chain length would lead to a faster dis-
sociation rate from the NK1-receptor.
Methods
The radioligand [O-methyl-11C]GR205171 was synthe-
sized from [11C]methyl iodide and O-desmethyl
GR205171 as previously described [20]. The ethyl ana-
logue (2S,3S)-N-(1-(2- [1-11C]ethoxy-5-(3-(trifluorome-
thyl)-4H-1,2,4-triazol-4-yl)phenyl)ethyl)-2-
phenylpiperidin-3-amine  (I)  and the propyl analogue
(2S,3S)-2-phenyl-N-(1-(2- [1-11C]propoxy-5-(3-(trifluor-
omethyl)-4H-1,2,4-triazol-4-yl)phenyl)ethyl)piperidin-
3-amine (II) were synthesized via alkylation of O-desme-
thyl GR205171 with [1-11C]ethyl iodide and [1-11C]pro-
pyl iodide, Figure 1. The following procedure was used;
dimethylformamide (300 μl) was added to O-desmethyl
GR205171 (1.0 mg, 2.3 μmol) and cesium carbonate (3.2
mg, 9.8 μmol) [35]. The solution was vortexed for approx-
imately 20 min before [1-11C]ethyl iodide or [1-11C]pro-
pyl iodide was transferred in a flow of nitrogen gas (30
mL/min) to the vial. The vial was then heated for 5 min at
140°C to yield the alkylated product. The product was
purified on a semi-preparative HPLC consisting of a Beck-
man 126 pump at 4 mL min-1, a Beckman 166 UV detec-
tor at 254 nm, a Bioscan β+-flow count detector, Gilson
231 XL auto injector, and a Beckman Ultrasphere ODS dp
5 μcolumn (250 × 10 mm). The mobile phase used was A)
0.05 M ammonium formate pH 3.5 and B) acetonitrile.
Compound (I): Gradient from 35% B to 48% over 8 min.
R.t 14.7 min. Compound (II): Isocratic elution 52% B, R.t
7.6 min. The mobile phase was removed using a rotavapor
at 90°C and reduced pressure. The product was formu-
lated in saline (2 mL), propylene glycol (2 mL), HCl (0.3
mL, 0.3 M) and ethanol (0.42 mL) and transferred from
the evaporator to a vial. The pH was adjusted to 7.0 with
phosphate/sodium hydroxide buffer prior to sterile filtra-
tion (Acrodisc Syringe Filters, 0.2 μm HT Tuffryn Mem-
brane). Analytical HPLC used to assess the radiochemical
purity was performed on a similar Beckman system
equipped with a Beckman Ultrasphere ODS dp 5 μcol-
umn (250 × 4.6 mm) and with the UV detector set to 254
nm. The mobile phase used was A) 0.05 M ammonium
formate pH 3.5, B) acetonitrile. Compound (I): Isocratic
elution 50% B, 1 mL min-1, R.t. 7.9 min, radiochemical
purity 97%. Compound (II): Isocratic elution 55% B, 1
mL min-1, r.t. 6.9 min, radiochemical purity 98%.
Male guinea-pigs weighing 350–500 g were housed under
standard laboratory conditions (20°C and 50% humid-
ity), maintained on a 12 h:12 h light/dark cycle and withBMC Medical Imaging 2007, 7:6 http://www.biomedcentral.com/1471-2342/7/6
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free access to food and water. The guinea-pig was placed
in a Plexiglass container and anesthetized with 3.8 % iso-
flurane prior to each experiment. When unconscious, the
animal was taken from the container and kept anesthe-
tized with 2.8% isoflurane via mask during the PET-scan.
A warm water pad was used to maintain the body temper-
ature at 36–37°C throughout the experiment. To assess
the status of the guinea pigs during anaesthesia the breath-
ing frequency was monitored and blood samples were
analysed for the following parameters: pH, HCO3, pCO2,
TCO2, sO2, pO2, Na, K, iCa, Hct and Hb. A catheter for
intravenous injection was inserted into the left femoral
vein. [O-methyl-11C]GR205171 (62, 59 and 29 MBq) and
(I) (8, 13 and 38 MBq) was administered to three animals
each and (II) (25 and 35 MBq) was administered to two
animals. The studies were performed using a microPET R4
tomograph (Concorde Microsystems) [36]. A transmis-
sion scan with rotating 57Co source was used to correct the
emission scan for the attenuation of 511 keV photons
through the tissue and scanner bed. The emission scan
was started when the radioligand was injected and contin-
ued for 90 min.
Two female rhesus monkeys, 8.0 kg and 9.5 kg, were
sedated with 100 mg intramuscular ketamine (Ketaminol,
Vetpharm AB) and transported to the investigation site at
Uppsala Imanet in the morning of the experiment.
Venous catheters were inserted in both hind legs of the
rhesus monkey. The catheters were used for administra-
tion of the radioligand, Ringer-Acetate (2 mL/kg/h,
Frensenius Kabi AB) and propofol (50 mg, Propofil-
Lipuro, B/Brown) to induce anaesthesia. Anaesthesia was
maintained with 1.3 – 2.5% sevoflurane via tracheal intu-
bation during the PET-scan. A femoral artery catheter was
inserted for blood sampling. Three PET-scans were carried
out 2 hrs apart in each monkey. Monkey 1 received [O-
methyl-11C]GR205171 (215 MBq), ligand (I) (54 MBq)
and ligand (I)  (30 MBq). Isotopically unmodified
GR205171 (0.5 mg/kg) was administered as a 10 min
infusion prior to the third scan. The same protocol was
used for monkey 2 which received [O-methyl-
11C]GR205171 (134 MBq), ligand (II)  (36 MBq) and
GR205171 (0.5 mg/kg) 10 min prior to administration of
ligand  (II)  (39 MBq). Arterial blood samples were
obtained at 1, 2.5, 5, 10, 20, 40, 60 and 90 min after radi-
oligand administration. Ventilation was supported with
30% oxygen in air and the body temperature was main-
tained at 37–38°C with heating pads. The studies were
performed using a PET/CT tomograph (Discovery ST16,
GE Healthcare). A CT scan was obtained to correct the
emission scan for the attenuation of 511 keV photons
through the tissue and head supports. The emission scan
began when the radioligand was injected and continued
for 90 min. The animal experiments were approved by the
Uppsala Animal Ethics Committee (C117/4).
The PET images were reconstructed using filtered backpro-
jection after correction for attenuation and scattered radi-
ation. The frame images were summarized and regions of
interest (ROI) were drawn in the striatum and cerebellum,
using rhesus monkey brain atlas for guidance (The rhesus
monkey brain in stereotaxic coordinates. Paxinos et al.,
2000). The tissue radioactivity was expressed as SUV
(Standardized Uptake Value).
Results and Discussion
[1-11C]Ethyl iodide and [1-11C]propyl iodide was synthe-
sized within 15 min from [11C]carbon monoxide, Figure
2. [1-11C]Ethyl iodide was synthesized via hydroxycarbo-
nylation of methyl iodide with a decay-corrected radio-
chemical yield of 55% [37]. [1-11C]Propyl iodide was
synthesized via hydroformylation of ethene with a decay
corrected radiochemical yield of 58% [38]. The specific
radioactivities at end of synthesis were 90 GBq/μmol and
270 GBq/μmol, respectively. The alkylation of O-desme-
thyl GR205171 led to O-alkylated and N-alkylated prod-
ucts in 1:7 ratio for both ethyl and propyl iodide. Based
on [11C]carbon monoxide, (I) and (II) were obtained in
5.1 ± 0.6% (n = 6) and 4.7 ± 0.8% (n = 7) isolated radio-
chemical yield, respectively. When the reaction tempera-
ture was lowered from 140°C to 110°C the yield of (I)
was reduced to 2.3 ± 0.6% (n = 5). The use of tetrabuty-
lammonium hydroxide instead of cesium carbonate
resulted in poorer radiochemical yield due to hydrolysis
of the labelled alkyl halides and a lower selectivity
towards O-alkylation compared to N-alkylation. Despite
the low selectivity of the alkylation reaction, a sufficient
amount of product was obtained for PET imaging in
guinea pig and rhesus monkey.
[O-methyl-11C]GR205171 and the two analogues were dis-
tributed into the guinea pig brain in a similar pattern. The
SUV
Measured Radioactivity in tissue
Injected Radioactivity
=
    
  / /Body Weight  
Synthesis of [O-methyl-11C]GR205171 and O-ethyl and O-pro- pyl analogues Figure 1
Synthesis of [O-methyl-11C]GR205171 and O-ethyl and O-pro-
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time-activity profiles obtained from the guinea pig PET
images showed an increase in striatum uptake throughout
the investigation for both analogues and [O-methyl-
11C]GR205171, Figure 3.
The SUV-values in guinea pig striatum were around 0.35–
0.85 at the end of the investigation. The values were low
compared to earlier studies with [O-methyl-
11C]GR205171 in rhesus monkeys which showed SUV-
values between 2 and 3 and similar shaped time-activity
curves [20]. The cerebellum uptake in the guinea pigs
increased during the first 30 min and remained constant
during the rest of the investigation with SUV-values
around 0.1 or less. Rupniak and co-workers have shown
that GR205171 brain uptake in P-glycoprotein deficient
mice was considerably higher than in wild type mice indi-
cating active efflux of GR205171 from the brain [39]. Sim-
ilarly, the low brain uptake of [O-methyl-11C]GR205171 in
guinea pig might be explained by active efflux mecha-
nisms.
PET images obtained from the studies in rhesus monkeys
are shown in Figure 4. [O-methyl-11C]GR205171 and the
two analogues were transported into the brain in a much
higher extent than in the guinea pigs. The ethyl-analogue
(I) showed binding in the striatum, but the ratio between
specific and unspecific binding was smaller than with [O-
methyl-11C]GR205171. The striatum could not be visual-
ised with (I)  after predosing with GR205171. A small
decrease in cerebellum uptake was also seen after predos-
ing. With the more lipophilic propyl-analogue (II) the
striatum could not be distinguished in the images either
with or without predosing.
The maximum SUV-values for [O-methyl-11C]GR205171
were 4.2 and 3.1 in monkey 1 and 2, respectively, Figure
5. The SUV values did not decline during the 90 min PET-
scan indicating that the binding was not reversible during
the investigation time. This was in accordance with earlier
reported results [20]. The uptake profiles were different
for the two analogues compared to [O-methyl-
11C]GR205171. The maximum SUV, 2.7 and 1.5 for the
ethyl- and propyl-analogues, respectively, was reached
within minutes after administration. Furthermore, the
analogues had a brain half-life of around 60 min and were
eliminated from the striatum, in difference to [O-methyl-
11C]GR205171. The SUV-values for (I)  were slightly
decreased when the NK1-receptors were blocked by pre-
dosing with GR205171. On the other hand, no such
change in SUV-values was observed for (II) after predos-
ing with GR205171. This indicated specific NK1-receptor
binding for the ethyl-analogue, while the propyl-analogue
was mainly unspecifically bound in the brain. The plasma
kinetics were similar for [O-methyl-11C]GR205171 and the
two analogues with a short distribution half-life and an
elimination phase half-life above 3 hrs.
PET-images over the transaxial rhesus monkey brain at the  level of striatum Figure 4
PET-images over the transaxial rhesus monkey brain at the 
level of striatum. Monkey 1: A. [O-methyl-11C]GR205171, B. 
Ethyl-analogue (I), C. Ethyl-analogue (I) after predosing with 
GR205171. Monkey 2: D. [O-methyl-11C]GR205171, E. Pro-
pyl-analogue (II), F. Propyl-analogue (II) after predosing with 
GR205171.
Synthesis of [1-11C]ethyl iodide and [1-11C]propyl iodide Figure 2
Synthesis of [1-11C]ethyl iodide and [1-11C]propyl iodide.
Time-activity profiles in guinea pig striatum after administra- tion of [O-methyl-11C]GR205171 (diamonds), ethyl-analogue  (I) (squares) and propyl-analogue (II) (triangles) Figure 3
Time-activity profiles in guinea pig striatum after administra-
tion of [O-methyl-11C]GR205171 (diamonds), ethyl-analogue 
(I) (squares) and propyl-analogue (II) (triangles). Each line 
represents uptake in one guinea pig.
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Conclusion
The rhesus monkey studies indicated that the order of lig-
and affinities for the NK1-receptor was [O-methyl-
11C]GR205171 > (I) > (II). The ethyl-analogue had a sim-
ilar binding pattern as [O-methyl-11C]GR205171, while no
specific binding to striatum could be detected for the pro-
pyl-analogue. The propyl-analogues can therefore not be
used for detecting changes in NK1-ligand levels, while fur-
ther studies should be performed with the ethyl analogue.
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